4:18 PM ET
10-Q
Financial Results
Semnur Pharmaceuticals Q3 2026 Results: Net Loss of $3.63M, Loss Narrows
Semnur Pharmaceuticals reported a net loss of $12.56 million for the nine months ended September 30, 2026, increasing its accumulated deficit to $288.36 million. The company maintains a significant stockholders' deficit of $33.31 million and relies heavily on a related party loan of $24.04 million to fund its operations.
- Key figure
- Net loss $3.63M